Inflammatory Bowel Disease

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

Adam S. Cheifetz, MD, director of the Center for Inflammatory Bowel Disease, medical director of Infusion Services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School, spoke with Healio about ulcerative colitis.

VANCOUVER, British Columbia — In this Healio video exclusive, Onyinye Ugonabo, MD, reviews the case of young patient who presented with symptoms of ulcerative colitis following discontinuation of growth hormone therapy.

The introduction of biologics as a therapeutic option for Crohn’s disease had “only a slight impact” on eventual surgery occurrence, although it may delay the first intestinal resection compared with conventional therapy, data showed.

Throughout 2023, gastroenterology societies made several significant clinical practice updates to guide diagnosis, management and treatment of various GI disorders such as celiac disease, inflammatory bowel disease and acute liver failure.

In the second half of 2023, there were numerous landmark FDA approvals for gastroenterology and hepatology, in particular for the treatment of ulcerative colitis, with four new options squeezing into an already saturated market.

The AGA has published the first comprehensive guideline on the management of pouchitis and other inflammatory pouch disorders among patients with ulcerative colitis who have undergone ileal pouch-anal anastomosis surgery.